Research ExplorerPublicationsAssociation of diabetes mellitus and metformin use with onco...

Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer

Standard

Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. / Rieken, Malte; Xylinas, Evanguelos; Kluth, Luis; Crivelli, Joseph J; Chrystal, James; Faison, Talia; Lotan, Yair; Karakiewicz, Pierre I; Fajkovic, Harun; Babjuk, Marek; Kautzky-Willer, Alexandra; Bachmann, Alexander; Scherr, Douglas S; Shariat, Shahrokh F.

In: BJU INT, Vol. 112, No. 8, 01.12.2013, p. 1105-12.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rieken, M, Xylinas, E, Kluth, L, Crivelli, JJ, Chrystal, J, Faison, T, Lotan, Y, Karakiewicz, PI, Fajkovic, H, Babjuk, M, Kautzky-Willer, A, Bachmann, A, Scherr, DS & Shariat, SF 2013, 'Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer', BJU INT, vol. 112, no. 8, pp. 1105-12. https://doi.org/10.1111/bju.12448

APA

Rieken, M., Xylinas, E., Kluth, L., Crivelli, J. J., Chrystal, J., Faison, T., Lotan, Y., Karakiewicz, P. I., Fajkovic, H., Babjuk, M., Kautzky-Willer, A., Bachmann, A., Scherr, D. S., & Shariat, S. F. (2013). Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU INT, 112(8), 1105-12. https://doi.org/10.1111/bju.12448

Vancouver

Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU INT. 2013 Dec 1;112(8):1105-12. https://doi.org/10.1111/bju.12448

Bibtex

@article{90e13d1cae9c4a29b38ab7ec112bf549,
title = "Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer",
abstract = "OBJECTIVE: To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007. Cox regression models were used to analyse the association of DM and metformin use with disease recurrence, disease progression, cancer-specific mortality and any-cause mortality.RESULTS: Of the 1117 patients, 125 (11.1%) had DM and 43 (3.8%) used metformin. Within a median (interquartile range) follow-up of 64 (22-106) months, 469 (42.0%) patients experienced disease recurrence, 103 (9.2%) experienced disease progression, 50 (4.5%) died from bladder cancer and 249 (22.3%) died from other causes. In multivariable Cox regression analyses, patients with DM who did not take metformin had a greater risk of disease recurrence (hazard ratio [HR]: 1.45, 95% confidence interval [CI] 1.09-1.94, P = 0.01) and progression (HR: 2.38, 95% CI 1.40-4.06, P = 0.001) but not any-cause mortality than patients without DM. DM with metformin use was independently associated with a lower risk of disease recurrence (HR: 0.50, 95% CI 0.27-0.94, P = 0.03).CONCLUSION: Patients with DM and NMIBC who do not take metformin seem to be at an increased risk of disease recurrence and progression; metformin use seems to exert a protective effect with regard to disease recurrence. The mechanisms behind the impact of DM on patients with NMIBC and the potential protective effect of metformin need further elucidation.",
keywords = "Aged, Aged, 80 and over, Diabetes Mellitus, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Urinary Bladder Neoplasms",
author = "Malte Rieken and Evanguelos Xylinas and Luis Kluth and Crivelli, {Joseph J} and James Chrystal and Talia Faison and Yair Lotan and Karakiewicz, {Pierre I} and Harun Fajkovic and Marek Babjuk and Alexandra Kautzky-Willer and Alexander Bachmann and Scherr, {Douglas S} and Shariat, {Shahrokh F}",
note = "{\textcopyright} 2013 The Authors. BJU International {\textcopyright} 2013 BJU International.",
year = "2013",
month = dec,
day = "1",
doi = "10.1111/bju.12448",
language = "English",
volume = "112",
pages = "1105--12",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer

AU - Rieken, Malte

AU - Xylinas, Evanguelos

AU - Kluth, Luis

AU - Crivelli, Joseph J

AU - Chrystal, James

AU - Faison, Talia

AU - Lotan, Yair

AU - Karakiewicz, Pierre I

AU - Fajkovic, Harun

AU - Babjuk, Marek

AU - Kautzky-Willer, Alexandra

AU - Bachmann, Alexander

AU - Scherr, Douglas S

AU - Shariat, Shahrokh F

N1 - © 2013 The Authors. BJU International © 2013 BJU International.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - OBJECTIVE: To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007. Cox regression models were used to analyse the association of DM and metformin use with disease recurrence, disease progression, cancer-specific mortality and any-cause mortality.RESULTS: Of the 1117 patients, 125 (11.1%) had DM and 43 (3.8%) used metformin. Within a median (interquartile range) follow-up of 64 (22-106) months, 469 (42.0%) patients experienced disease recurrence, 103 (9.2%) experienced disease progression, 50 (4.5%) died from bladder cancer and 249 (22.3%) died from other causes. In multivariable Cox regression analyses, patients with DM who did not take metformin had a greater risk of disease recurrence (hazard ratio [HR]: 1.45, 95% confidence interval [CI] 1.09-1.94, P = 0.01) and progression (HR: 2.38, 95% CI 1.40-4.06, P = 0.001) but not any-cause mortality than patients without DM. DM with metformin use was independently associated with a lower risk of disease recurrence (HR: 0.50, 95% CI 0.27-0.94, P = 0.03).CONCLUSION: Patients with DM and NMIBC who do not take metformin seem to be at an increased risk of disease recurrence and progression; metformin use seems to exert a protective effect with regard to disease recurrence. The mechanisms behind the impact of DM on patients with NMIBC and the potential protective effect of metformin need further elucidation.

AB - OBJECTIVE: To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007. Cox regression models were used to analyse the association of DM and metformin use with disease recurrence, disease progression, cancer-specific mortality and any-cause mortality.RESULTS: Of the 1117 patients, 125 (11.1%) had DM and 43 (3.8%) used metformin. Within a median (interquartile range) follow-up of 64 (22-106) months, 469 (42.0%) patients experienced disease recurrence, 103 (9.2%) experienced disease progression, 50 (4.5%) died from bladder cancer and 249 (22.3%) died from other causes. In multivariable Cox regression analyses, patients with DM who did not take metformin had a greater risk of disease recurrence (hazard ratio [HR]: 1.45, 95% confidence interval [CI] 1.09-1.94, P = 0.01) and progression (HR: 2.38, 95% CI 1.40-4.06, P = 0.001) but not any-cause mortality than patients without DM. DM with metformin use was independently associated with a lower risk of disease recurrence (HR: 0.50, 95% CI 0.27-0.94, P = 0.03).CONCLUSION: Patients with DM and NMIBC who do not take metformin seem to be at an increased risk of disease recurrence and progression; metformin use seems to exert a protective effect with regard to disease recurrence. The mechanisms behind the impact of DM on patients with NMIBC and the potential protective effect of metformin need further elucidation.

KW - Aged

KW - Aged, 80 and over

KW - Diabetes Mellitus

KW - Disease Progression

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hypoglycemic Agents

KW - Male

KW - Metformin

KW - Middle Aged

KW - Neoplasm Invasiveness

KW - Neoplasm Recurrence, Local

KW - Predictive Value of Tests

KW - Prognosis

KW - Proportional Hazards Models

KW - Retrospective Studies

KW - Treatment Outcome

KW - Urinary Bladder Neoplasms

U2 - 10.1111/bju.12448

DO - 10.1111/bju.12448

M3 - SCORING: Journal article

C2 - 24053906

VL - 112

SP - 1105

EP - 1112

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 8

ER -